Business
AGM and Board Update
AGM and Board Update.
About this update from Immupharma Plc
[{"type":"text","content":"\n Immupharma PLC\n13 June 2007\n\n\nFor Immediate Release 13 June 2007\n\n\n ImmuPharma PLC\n\n AGM Statement and Board Update\n\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug\ndiscovery and development company, held its AGM earlier today and is pleased to\nannounce that all resolutions were passed.\n\nPaddy Walker-Taylor, 60, currently part-time finance director, has decided by\nmutual agreement with the company to resign his role as director but remain with\nthe company on a reduced-time basis.\n\nThe Board wishes to thank Mr Walker-Taylor for his support during the early\nphase of the company and look forward to continuing working together.\n\nDr. Robert Zimmer, MD, PhD, President & head of R&D, said 'we are delighted with\nthe achievements in our R&D activities and in particular, the progress in the\npreparation of the phase II/III in the US and Europe, for which we hope to\nsubmit the file to the FDA in the next few weeks with the view of starting the\nphase II/III trial later this year.'\n\n\nFor further information please contact:\n\nImmuPharma PLC:\nDimitri Dimitriou, Chief Executive +44 20 7152 4080\nOfficer\nRichard Warr, Chairman +44 20 7152 4080\nDr Robert Zimmer, President & Chief + 33 389 32 76 50\nScientific Officer\n\nBuchanan Communications + 44 20 7466 5000\nLisa Baderoon\nRebecca Skye Dietrich\n\n\nNotes to Editors:\n\n\nAbout ImmuPharma\n\nImmuPharma PLC is a drug discovery and development company headquartered in\nLondon, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has\nresearch operations in France (ImmuPharma (France) SA) and Switzerland\n(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,\nlargely based on peptide therapeutics, to treat serious medical conditions such\nas autoimmune diseases characterised by:\n\n* blockbuster potential in niche markets\n\n* low promotional costs in few specialised physicians and centres and\n\n* lower risk of drug development and lower development costs\n\nImmuPharma is a currently developing drug candidates for three different medical\nconditions, each of which would represent a significant breakthrough in its\nfield. The furthest advanced drug candidate targets Lupus, a disease for which\nthere is currently no cure or specific treatment. The other two address moderate\nto sev...